UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 345

Sortiert nach

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

Journal of clinical oncology, 2019-10, Vol.37 (30), p.JCO1900318-2737

2019

Volltextzugriff (PDF)

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

The Lancet (British edition), 2014-07, Vol.384 (9938), p.164-172

2014

Volltextzugriff (PDF)

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Clinical cancer research, 2014-09, Vol.20 (17), p.4436-4441

2014

Volltextzugriff (PDF)

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer

Clinical cancer research, 2015-06, Vol.21 (11), p.2436-2439

2015

Volltextzugriff (PDF)

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (7), p.1850-1854

2021

Volltextzugriff (PDF)

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

Clinical cancer research, 2020-08, Vol.26 (16), p.4180-4185

2020

Volltextzugriff (PDF)

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (9), p.2378-2382

2021

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

Clinical cancer research, 2014-04, Vol.20 (8), p.2029-2034

2014

Volltextzugriff (PDF)

Biomechanical characterization of firefighters running under different rescue tasks

Scientific reports, 2024-01, Vol.14 (1), p.1813-1813, Article 1813

2024

Volltextzugriff (PDF)

Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials

The lancet oncology, 2022-05, Vol.23 (5), p.e229-e234

2022

Volltextzugriff (PDF)

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

Clinical cancer research, 2014, Vol.20 (1), p.9-14

2014

Volltextzugriff (PDF)

FDA Approval Summary: Sunitinib for the Treatment of Progressive Well‐Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

The oncologist (Dayton, Ohio), 2012-08, Vol.17 (8), p.1108-1113

2012

Volltextzugriff (PDF)

Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

Clinical cancer research, 2006-12, Vol.12 (24), p.7271-7278

2006

Volltextzugriff (PDF)

Single-stage debridement via autogenous iliac bone graft through the OLIF corridor and lateral fixation in treating spontaneous single-level lumbar pyogenic spondylodiscitis

BMC musculoskeletal disorders, 2021-11, Vol.22 (1), p.1-947, Article 947

2021

Volltextzugriff (PDF)

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

Clinical cancer research, 2013-09, Vol.19 (18), p.4911-4916

2013

Volltextzugriff (PDF)

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Clinical cancer research, 2007-03, Vol.13 (5), p.1367-1373

2007

Volltextzugriff (PDF)

Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

Clinical cancer research, 2013-12, Vol.19 (24), p.6650-6656

2013

Volltextzugriff (PDF)

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1225-1231

2018

Volltextzugriff (PDF)

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e005344

2023

Volltextzugriff (PDF)

Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non‐Small Cell Lung Cancer (NSCLC)

The oncologist (Dayton, Ohio), 2010-12, Vol.15 (12), p.1344-1351

2010

Volltextzugriff (PDF)

Overestimation of the Effect Size in Group Sequential Trials

Clinical cancer research, 2012-09, Vol.18 (18), p.4872-4876

2012

Volltextzugriff (PDF)

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

Clinical cancer research, 2010-10, Vol.16 (20), p.4921-4927

2010

Volltextzugriff (PDF)

Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2171-2178

2001

Volltextzugriff (PDF)

Multiconfigurational actinide nitrides assisted by double Möbius aromaticity

Chemical science (Cambridge), 2024-05, Vol.15 (21), p.8216-8226

2024

Volltextzugriff (PDF)

1 – 25 von 345

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(320)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(267)
Life Sciences & Biomedicine
(186)
Humans
(110)
Oncology
(86)
Technology
(68)
Female
(55)
United States
(52)
Male
(47)
United States Food And Drug Administration
(46)
Physical Sciences
(40)
Adult
(39)
Drug Approval
(39)
Engineering
(36)
Aged
(33)
Middle Aged
(30)
Environmental Sciences & Ecology
(29)
Treatment Outcome
(27)
Environmental Sciences
(23)
Materials Science
(21)
Animals
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(46)
Journal Of Clinical Oncology
(40)
The Oncologist
(11)
The oncologist
(11)
Acs Applied Materials & Interfaces
(8)
Cancer Research
(6)
The Science Of The Total Environment
(5)
Chemical Science
(4)
Jama Oncology
(4)
Land
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

Biomechanical characterization of firefighters running under different rescue tasks

Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

FDA Approval Summary: Sunitinib for the Treatment of Progressive Well‐Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

Single-stage debridement via autogenous iliac bone graft through the OLIF corridor and lateral fixation in treating spontaneous single-level lumbar pyogenic spondylodiscitis

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non‐Small Cell Lung Cancer (NSCLC)

Overestimation of the Effect Size in Group Sequential Trials

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

Multiconfigurational actinide nitrides assisted by double Möbius aromaticity

Suchergebnisse filtern